 InVivo Therapeutics Holdings Corp. NVIV today announced the pricing of a public offering of 2,545,455 shares of its common stock or pre-funded warrants to purchase common stock in lieu thereof, together with warrants to purchase up to 2,545,455 shares of common stock at a combined effective price to the public of 2.75 per share or pre-funded warrant and associated warrant. The gross proceeds from this offering are expected to be approximately 7.0 million, before deducting the placement agent fees and estimated offering expenses payable by InVivo Therapeutics. 